- Report
- December 2024
- 150 Pages
Global
From €5408EUR$5,950USD£4,592GBP
- Report
- May 2024
- 139 Pages
Global
From €5907EUR$6,499USD£5,016GBP
- Report
- October 2024
- 184 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- July 2024
- 202 Pages
Global
From €5408EUR$5,950USD£4,592GBP
- Report
- April 2025
- 364 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2272EUR$2,500USD£1,930GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1136EUR$1,250USD£965GBP
- Report
- December 2024
- 84 Pages
Global
From €3590EUR$3,950USD£3,049GBP
- Report
- April 2025
- 183 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- January 2025
- 200 Pages
Global
From €4540EUR$4,995USD£3,855GBP
- Report
- November 2018
- 147 Pages
Global
From €1250EUR$1,375USD£1,061GBP
€2500EUR$2,750USD£2,123GBP
- Report
- November 2023
- 140 Pages
Global
From €4045EUR$4,450USD£3,435GBP
- Report
- July 2023
- 135 Pages
Global
From €6817EUR$7,500USD£5,789GBP
- Report
- February 2024
- 168 Pages
Global
From €7226EUR$7,950USD£6,136GBP
- Report
- July 2023
- 67 Pages
Global
From €3590EUR$3,950USD£3,049GBP
- Report
- December 2023
- 168 Pages
Global
From €4498EUR$4,949USD£3,820GBP
- Report
- October 2023
- 145 Pages
Global
From €2863EUR$3,150USD£2,431GBP
- Report
- October 2023
- 145 Pages
Global
From €2863EUR$3,150USD£2,431GBP
- Report
- November 2023
- 189 Pages
Global
From €4090EUR$4,500USD£3,473GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more